NasdaqGS - Nasdaq Real Time Price USD

Illumina, Inc. (ILMN)

Compare
154.96 +1.47 (+0.96%)
At close: November 5 at 4:00 PM EST
153.30 -1.66 (-1.07%)
After hours: 7:20 PM EST
Loading Chart for ILMN
DELL
  • Previous Close 153.49
  • Open 148.15
  • Bid 146.39 x 100
  • Ask 155.51 x 100
  • Day's Range 147.41 - 156.66
  • 52 Week Range 86.58 - 156.66
  • Volume 3,492,655
  • Avg. Volume 1,729,290
  • Market Cap (intraday) 24.685B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -19.34
  • Earnings Date Nov 7, 2024 - Nov 11, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 158.36

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

www.illumina.com

10,590

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ILMN

View More

Performance Overview: ILMN

Trailing total returns as of 11/5/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ILMN
14.41%
S&P 500
21.24%

1-Year Return

ILMN
36.25%
S&P 500
32.68%

3-Year Return

ILMN
62.24%
S&P 500
23.56%

5-Year Return

ILMN
47.54%
S&P 500
87.86%

Compare To: ILMN

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ILMN

View More

Valuation Measures

Annual
As of 11/5/2024
  • Market Cap

    24.69B

  • Enterprise Value

    26.35B

  • Trailing P/E

    --

  • Forward P/E

    34.97

  • PEG Ratio (5yr expected)

    0.73

  • Price/Sales (ttm)

    5.60

  • Price/Book (mrq)

    11.62

  • Enterprise Value/Revenue

    6.00

  • Enterprise Value/EBITDA

    102.12

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -36.11%

  • Return on Assets (ttm)

    2.97%

  • Return on Equity (ttm)

    -39.51%

  • Revenue (ttm)

    4.39B

  • Net Income Avi to Common (ttm)

    -1.58B

  • Diluted EPS (ttm)

    -19.34

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    939M

  • Total Debt/Equity (mrq)

    122.40%

  • Levered Free Cash Flow (ttm)

    491.25M

Research Analysis: ILMN

View More

Company Insights: ILMN

Research Reports: ILMN

View More

People Also Watch